<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01234675</url>
  </required_header>
  <id_info>
    <org_study_id>SAV-MD-17</org_study_id>
    <nct_id>NCT01234675</nct_id>
  </id_info>
  <brief_title>The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia</brief_title>
  <official_title>The Effects of Milnacipran on Sleep Disturbance in Fibromyalgia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoor Ahmed M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Forest Laboratories</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Cleveland Sleep Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Fibromyalgia is a condition of chronic widespread pain, sleep disturbance and fatigue. Most
      of the patients with fibromyalgia complain of either non-restorative sleep or complaints of
      disturbed sleep due to pain. The study aimed at examining the effects of milnacipran on sleep
      disturbance in patients with fibromyalgia. The study is a randomized, double-blind, placebo
      controlled, two way crossover polysomnography (PSG) study to explore the effects of
      milnacipran on sleep disturbance. Patients received either milnacipran 50 mg twice a day
      (BID) or matching placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The sleep disturbance in fibromyalgia is characterized as non-restorative in nature, and is
      defined as a feeling of light sleep, independent of duration, and as non-refreshing. As such,
      these patients wake up in the morning and complain of stiffness and overall aching of the
      body.

      It is well known that reciprocal relationship exists between sleep and pain, with sleep
      disturbances being an important contributor to morbidity in fibromyalgia. Milnacipran, a
      selective serotonin norepinephrine receptor inhibitor (SNRI), was approved by the Food and
      Drug Administration (FDA) for the management of fibromyalgia. Although milnacipran has
      extensively been studied in fibromyalgia patients, but there is no objective measure, i.e.,
      the use of overnight polysomnography, to determine its effects on sleep.

      The study was undertaken to evaluate the effects of milnacipran on PSG determined measures of
      sleep in patients with fibromyalgia. The study also evaluated the impact of milnacipran on
      subjective measures of sleep and fibromyalgia symptoms.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">February 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Awakenings After Sleep Onset (NAASO)</measure>
    <time_frame>4-Week maintenance treatment with milnacipran and placebo</time_frame>
    <description>Number of awakenings after defined sleep onset until lights on.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sleep Efficiency (SE)</measure>
    <time_frame>4-Week maintenance treatment with milnacipran and placebo</time_frame>
    <description>Percentage of time spent asleep while in bed</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Wake After Sleep Onset (WASO)</measure>
    <time_frame>4-Week maintenance treatment with milnacipran and placebo</time_frame>
    <description>Wake time after defined sleep onset until lights on.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Latency to Persistent Sleep Onset (LPS)</measure>
    <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
    <description>It is defined as time from lights out to the first consecutive 2 minutes of uninterrupted sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Sleep Time (TST)</measure>
    <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
    <description>Total sleep of all Rapid Eye Movement (REM) and Non- Rapid Eye Movement Sleep (NTREM) from lights out to lights on.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arousal Index (AI)</measure>
    <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
    <description>Number of arousals per hour of sleep</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slow Wave Sleep (SWS)</measure>
    <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
    <description>Time spent in stage 3 of non-rapid eye movement sleep and often referred to as deep sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Problem Index 2, Medical Outcomes Study Sleep Scale (MOS-SS)</measure>
    <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
    <description>This is a subjective index derived from the medical outcomes study sleep scale (MOS-SS) scored on a 0-100 possible range with higher scores indicating more severe sleep disruption. The scale is a self-report instrument consisting of 12 items that assess perceived initiation and maintenance of sleep, respiratory problems during sleep, sleep duration, perceived adequacy of sleep and daytime somnolence.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality Scale</measure>
    <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
    <description>Sleep quality measure derived from daily sleep diary rating ranging from 0 (&quot;very poor&quot;) to 10 (&quot;excellent&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue Severity Scale (FSS) Total Score</measure>
    <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
    <description>The scale is a 9-item self-report of fatigue in the past week and scored on a 7-point scale with 1 = strongly disagree and 7 = strongly agree. Scores range from 9 to 63 with higher scores indicating higher fatigue severity. A total score greater or equal to 36 suggests fatigue.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fibromyalgia Impact Questionnaire (FIQ) Total Score</measure>
    <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
    <description>The scale is composed of 10 items relating to fibromyalgia symptoms experienced in the past week. Score ranges from 0 to 100 with higher scores indicating a greater effect of fibromyalgia on a person's life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Mean Severity Score</measure>
    <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
    <description>The score is derived from the BPI scale and measures pain intensity in the past 24 hour. The pain severity score is derived as the average score of 4 pain items assessing pain at its &quot;worst&quot;, &quot;least&quot;, &quot;average&quot; and &quot;now&quot; and ranges from 0-10 with higher scores reflecting greater pain</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Brief Pain Inventory (BPI) Mean Interference Score</measure>
    <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
    <description>The score is derived from the BPI scale and measures the effect of pain on functioning in the past 24 hour. It is the average score of 7 items interfering with general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. Score ranges from 0-10 with higher scores reflecting greater interference.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Sleep Disorders</condition>
  <condition>Fibromyalgia</condition>
  <condition>Sleep</condition>
  <arm_group>
    <arm_group_label>milnacipran</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: milnacipran 7-day dose escalation, 28- day treatment with milnacipran 50 mg and 7-day taper period before or after crossover to placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Drug: placebo 45-day placebo treatment before or after crossover to milnacipran</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Milnacipran</intervention_name>
    <description>50 mg twice daily</description>
    <arm_group_label>milnacipran</arm_group_label>
    <other_name>Savella</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>50 mg twice daily</description>
    <arm_group_label>placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men or women at least 18 years or older

          2. Diagnosis of fibromyalgia

          3. Clinically significant sleep disturbance, defined as difficulty in maintaining sleep
             (wake after sleep onset and arousal index) at least three times per week for at least
             one month

          4. Understand and willing to cooperate with the study procedures

          5. Maintain a normal sleep schedule, with daytime-awake and nighttime-sleep schedule,
             with customary bedtime between 9 PM and midnight, and rise time 5 AM and 9 AM

          6. Patients who are able to speak, read, and understand English language and able to
             follow the study protocol, and are able to sign the informed consent

        Exclusion Criteria:

          1. Subject has any of the following medical conditions:

             Liver disease, blood disorder, autoimmune disease, endocrine, cardiovascular,
             hypertension, renal, hepatic, gastrointestinal, or neurological disorder, active
             peptic ulcer or inflammatory bowel disease

          2. Significant sleep apnea

          3. Periodic leg movement disorder (PLMD) or restless legs syndrome (RLS)

          4. Any form of severe psychiatric illness, moderate to severe depression, including
             significant risk of suicide

          5. Patients with uncontrolled glaucoma

          6. Inability to discontinue the prohibited medications

          7. Female of childbearing potential not using birth control measures; or lactating.

          8. History of alcohol, narcotic, benzodiazepines or other substance abuse within the past
             one year.

          9. Patient on prohibited medication will include but not limited to:

               -  Anxiolytics, anti-convulsants, antipsychotics, lithium, barbiturates,
                  anti-histamines, monoamine oxidase inhibitors, or medications that affect sleep

               -  Any prescription or over the counter stimulants

               -  Medications that are contraindicated with the use of milnacipran

         10. Excessive caffeine use, defined as a consumption of more than 500 mg of caffeine or
             other xanthines, smoking &gt;1/2 a pack/day or alcohol use &gt;14 units/week

         11. History of allergy to milnacipran.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mansoor Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cleveland Sleep Research Cneter</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rozina Aamir, MS, MBA</last_name>
    <role>Study Director</role>
    <affiliation>Cleveland Sleep Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Noel Cyrill, MD</last_name>
    <role>Study Director</role>
    <affiliation>SouthWest Cleveland Sleep Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nosson S Goldfarb, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Cleveland Sleep Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cleveland Sleep Research Center</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 3, 2010</study_first_submitted>
  <study_first_submitted_qc>November 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 4, 2010</study_first_posted>
  <results_first_submitted>February 5, 2015</results_first_submitted>
  <results_first_submitted_qc>July 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 22, 2015</results_first_posted>
  <last_update_submitted>August 7, 2019</last_update_submitted>
  <last_update_submitted_qc>August 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Cleveland Sleep Research Center</investigator_affiliation>
    <investigator_full_name>Mansoor Ahmed M.D.</investigator_full_name>
    <investigator_title>Medical Director</investigator_title>
  </responsible_party>
  <keyword>Fibromyalgia</keyword>
  <keyword>Sleep disorders</keyword>
  <keyword>Forest Laboratories</keyword>
  <keyword>Milnacipran</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibromyalgia</mesh_term>
    <mesh_term>Myofascial Pain Syndromes</mesh_term>
    <mesh_term>Sleep Wake Disorders</mesh_term>
    <mesh_term>Parasomnias</mesh_term>
    <mesh_term>Dyssomnias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Milnacipran</mesh_term>
    <mesh_term>Levomilnacipran</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo Then Milnacipran</title>
          <description>50 mg twice daily (BID) maintenance dose</description>
        </group>
        <group group_id="P2">
          <title>Milnacipran Then Placebo</title>
          <description>50 mg twice daily (BID) maintenance dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention (6 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>2 treatment period, with each period 6 weeks and 7 day washout period Milnacipran in treatment period 1, Placebo in treatment period 2 Placebo treatment in Period 1, and Milnacipran in Period 2</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="19"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.2" lower_limit="28" upper_limit="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Baseline polysomnographic sleep parameters</title>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Latency to persistent sleep (LPS)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49.4" spread="43.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total sleep time (TST)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="340.7" spread="78.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wake after sleep onset (WASO)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="97.2" spread="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of awakenings after sleep onset (NAASO)</title>
          <units>awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31.9" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sleep efficiency (SE)</title>
          <units>percentage of total sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="72.3" spread="15.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Arousal index (AI)</title>
          <units>arousals per hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24.8" spread="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total stage shifts</title>
          <description>Sleep stage shifts: stage 1, stage 2, stage 3, REM sleep</description>
          <units>Stage shifts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="147.4" spread="42.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Rapid Eye Movement (REM) latency</title>
          <description>Time from sleep onset to the first epoch of rapid eye movement (REM) sleep</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="126.5" spread="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sleep architecture</title>
          <description>Pattern of sleep as it shifts between the different sleep stages. Sleep stages 1-3 are collectively referred to as non--rapid eye movement sleep (NREM)</description>
          <units>percentage of total sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Stage N1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.9" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage N2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.0" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stage N3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.2" spread="8.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>REM Sleep</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.0" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Awakenings After Sleep Onset (NAASO)</title>
        <description>Number of awakenings after defined sleep onset until lights on.</description>
        <time_frame>4-Week maintenance treatment with milnacipran and placebo</time_frame>
        <population>15 subjects completed the study</population>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Awakenings After Sleep Onset (NAASO)</title>
          <description>Number of awakenings after defined sleep onset until lights on.</description>
          <population>15 subjects completed the study</population>
          <units>Awakenings</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.5" spread="4.5"/>
                    <measurement group_id="O2" value="34.9" spread="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.424</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>4.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-7.3</ci_lower_limit>
            <ci_upper_limit>16.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Sleep Efficiency (SE)</title>
        <description>Percentage of time spent asleep while in bed</description>
        <time_frame>4-Week maintenance treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Efficiency (SE)</title>
          <description>Percentage of time spent asleep while in bed</description>
          <units>percentage of total sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.1" spread="3.8"/>
                    <measurement group_id="O2" value="83.3" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.049</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>-6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.2</ci_lower_limit>
            <ci_upper_limit>-0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Wake After Sleep Onset (WASO)</title>
        <description>Wake time after defined sleep onset until lights on.</description>
        <time_frame>4-Week maintenance treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Wake After Sleep Onset (WASO)</title>
          <description>Wake time after defined sleep onset until lights on.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2" spread="10.8"/>
                    <measurement group_id="O2" value="53.6" spread="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.056</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>22.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.6</ci_lower_limit>
            <ci_upper_limit>45.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Latency to Persistent Sleep Onset (LPS)</title>
        <description>It is defined as time from lights out to the first consecutive 2 minutes of uninterrupted sleep.</description>
        <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Latency to Persistent Sleep Onset (LPS)</title>
          <description>It is defined as time from lights out to the first consecutive 2 minutes of uninterrupted sleep.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.6" spread="6.2"/>
                    <measurement group_id="O2" value="38.6" spread="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.683</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>-6.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.5</ci_lower_limit>
            <ci_upper_limit>18.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Sleep Time (TST)</title>
        <description>Total sleep of all Rapid Eye Movement (REM) and Non- Rapid Eye Movement Sleep (NTREM) from lights out to lights on.</description>
        <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Total Sleep Time (TST)</title>
          <description>Total sleep of all Rapid Eye Movement (REM) and Non- Rapid Eye Movement Sleep (NTREM) from lights out to lights on.</description>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="361.7" spread="19.6"/>
                    <measurement group_id="O2" value="386.1" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.155</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>-1.502</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-59.1</ci_lower_limit>
            <ci_upper_limit>10.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arousal Index (AI)</title>
        <description>Number of arousals per hour of sleep</description>
        <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Arousal Index (AI)</title>
          <description>Number of arousals per hour of sleep</description>
          <units>arousals per hour</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.2" spread="2.2"/>
                    <measurement group_id="O2" value="31.2" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.805</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>7.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Slow Wave Sleep (SWS)</title>
        <description>Time spent in stage 3 of non-rapid eye movement sleep and often referred to as deep sleep.</description>
        <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Slow Wave Sleep (SWS)</title>
          <description>Time spent in stage 3 of non-rapid eye movement sleep and often referred to as deep sleep.</description>
          <units>percentage of total sleep time</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.4" spread="2.7"/>
                    <measurement group_id="O2" value="9.4" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.844</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>-1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.6</ci_lower_limit>
            <ci_upper_limit>9.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Problem Index 2, Medical Outcomes Study Sleep Scale (MOS-SS)</title>
        <description>This is a subjective index derived from the medical outcomes study sleep scale (MOS-SS) scored on a 0-100 possible range with higher scores indicating more severe sleep disruption. The scale is a self-report instrument consisting of 12 items that assess perceived initiation and maintenance of sleep, respiratory problems during sleep, sleep duration, perceived adequacy of sleep and daytime somnolence.</description>
        <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Problem Index 2, Medical Outcomes Study Sleep Scale (MOS-SS)</title>
          <description>This is a subjective index derived from the medical outcomes study sleep scale (MOS-SS) scored on a 0-100 possible range with higher scores indicating more severe sleep disruption. The scale is a self-report instrument consisting of 12 items that assess perceived initiation and maintenance of sleep, respiratory problems during sleep, sleep duration, perceived adequacy of sleep and daytime somnolence.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.8" spread="4.4"/>
                    <measurement group_id="O2" value="34.9" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.509</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>2.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.4</ci_lower_limit>
            <ci_upper_limit>12.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sleep Quality Scale</title>
        <description>Sleep quality measure derived from daily sleep diary rating ranging from 0 (&quot;very poor&quot;) to 10 (&quot;excellent&quot;)</description>
        <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Sleep Quality Scale</title>
          <description>Sleep quality measure derived from daily sleep diary rating ranging from 0 (&quot;very poor&quot;) to 10 (&quot;excellent&quot;)</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="0.52"/>
                    <measurement group_id="O2" value="4.9" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.3</ci_lower_limit>
            <ci_upper_limit>0.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fatigue Severity Scale (FSS) Total Score</title>
        <description>The scale is a 9-item self-report of fatigue in the past week and scored on a 7-point scale with 1 = strongly disagree and 7 = strongly agree. Scores range from 9 to 63 with higher scores indicating higher fatigue severity. A total score greater or equal to 36 suggests fatigue.</description>
        <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Fatigue Severity Scale (FSS) Total Score</title>
          <description>The scale is a 9-item self-report of fatigue in the past week and scored on a 7-point scale with 1 = strongly disagree and 7 = strongly agree. Scores range from 9 to 63 with higher scores indicating higher fatigue severity. A total score greater or equal to 36 suggests fatigue.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" spread="3.4"/>
                    <measurement group_id="O2" value="42.3" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.685</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>-1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-8.2</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fibromyalgia Impact Questionnaire (FIQ) Total Score</title>
        <description>The scale is composed of 10 items relating to fibromyalgia symptoms experienced in the past week. Score ranges from 0 to 100 with higher scores indicating a greater effect of fibromyalgia on a person's life.</description>
        <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Fibromyalgia Impact Questionnaire (FIQ) Total Score</title>
          <description>The scale is composed of 10 items relating to fibromyalgia symptoms experienced in the past week. Score ranges from 0 to 100 with higher scores indicating a greater effect of fibromyalgia on a person's life.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0" spread="6.8"/>
                    <measurement group_id="O2" value="45.3" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.349</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>-5.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-17.0</ci_lower_limit>
            <ci_upper_limit>6.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Pain Inventory (BPI) Mean Severity Score</title>
        <description>The score is derived from the BPI scale and measures pain intensity in the past 24 hour. The pain severity score is derived as the average score of 4 pain items assessing pain at its &quot;worst&quot;, &quot;least&quot;, &quot;average&quot; and &quot;now&quot; and ranges from 0-10 with higher scores reflecting greater pain</description>
        <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory (BPI) Mean Severity Score</title>
          <description>The score is derived from the BPI scale and measures pain intensity in the past 24 hour. The pain severity score is derived as the average score of 4 pain items assessing pain at its &quot;worst&quot;, &quot;least&quot;, &quot;average&quot; and &quot;now&quot; and ranges from 0-10 with higher scores reflecting greater pain</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1" spread="0.6"/>
                    <measurement group_id="O2" value="4.7" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.305</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>-0.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>5.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Brief Pain Inventory (BPI) Mean Interference Score</title>
        <description>The score is derived from the BPI scale and measures the effect of pain on functioning in the past 24 hour. It is the average score of 7 items interfering with general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. Score ranges from 0-10 with higher scores reflecting greater interference.</description>
        <time_frame>4-Week treatment with milnacipran and placebo</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Milnacipran</title>
            <description>Treatment with 50 mg BiD</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>50 mg placebo BiD</description>
          </group>
        </group_list>
        <measure>
          <title>Brief Pain Inventory (BPI) Mean Interference Score</title>
          <description>The score is derived from the BPI scale and measures the effect of pain on functioning in the past 24 hour. It is the average score of 7 items interfering with general activity, mood, walking ability, normal work, relations with other people, sleep and enjoyment of life. Score ranges from 0-10 with higher scores reflecting greater interference.</description>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="0.6"/>
                    <measurement group_id="O2" value="4.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.425</p_value>
            <method>Paired T test</method>
            <param_type>Paired difference</param_type>
            <param_value>-0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.8</ci_lower_limit>
            <ci_upper_limit>0.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected on and after Day 1 of the first treatment period. The data collection continued till the two weeks after the second treatment period.</time_frame>
      <desc>Additional data was collected after the end of study visit if the patient reported an adverse event.</desc>
      <group_list>
        <group group_id="E1">
          <title>Milnacipran</title>
          <description>Drug: milnacipran, 50 mg twice daily for 4 weeks.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Drug: Placebo 50 mg, twice daily for 4 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gall Stones</sub_title>
                <description>During the study the subject was diagnosed with having gall stones. After the blind was broken, the site found out that she was on placebo, and was never treated with the study drug.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Increased Heartrate</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Elevated Blood Pressure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <description>nausea and vomiting</description>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Increased Perspirations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Cold sweats</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Petechial rash</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Foot sprain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Worsening of pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive urination</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Excessive menstrual bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Abnormal ejaculation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>cold/flu</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="19"/>
              </event>
              <event>
                <sub_title>Streptococcal infection (throat)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="19"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>A well-established adaptation and re-adaptation to laboratory effects may have compromised our results. Other study biases include biases inherent in the crossover design, and a small sample size.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Mansoor Ahmed, MD</name_or_title>
      <organization>Cleveland Sleep Research Center</organization>
      <phone>4402438044</phone>
      <email>sleepresearchcenter@yahoo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

